» Articles » PMID: 37680650

Unleashing Nature's Potential and Limitations: Exploring Molecular Targeted Pathways and Safe Alternatives for the Treatment of Multiple Sclerosis (Review)

Overview
Journal Med Int (Lond)
Specialty General Medicine
Date 2023 Sep 8
PMID 37680650
Authors
Affiliations
Soon will be listed here.
Abstract

Driven by the limitations and obstacles of the available approaches and medications for multiple sclerosis (MS) that still cannot treat the disease, but only aid in accelerating the recovery from its attacks, the use of naturally occurring molecules as a potentially safe and effective treatment for MS is being explored in model organisms. MS is a devastating disease involving the brain and spinal cord, and its symptoms vary widely. Multiple molecular pathways are involved in the pathogenesis of the disease. The present review showcases the recent advancements in harnessing nature's resources to combat MS. By deciphering the molecular pathways involved in the pathogenesis of the disease, a wealth of potential therapeutic agents is uncovered that may revolutionize the treatment of MS. Thus, a new hope can be envisioned in the future, aiming at paving the way toward identifying novel safe alternatives to improve the lives of patients with MS.

References
1.
Jomova K, Valko M . Advances in metal-induced oxidative stress and human disease. Toxicology. 2011; 283(2-3):65-87. DOI: 10.1016/j.tox.2011.03.001. View

2.
Abd El Mohsen M, Gunter Kuhnle , Rechner A, Schroeter H, Rose S, Jenner P . Uptake and metabolism of epicatechin and its access to the brain after oral ingestion. Free Radic Biol Med. 2002; 33(12):1693-702. DOI: 10.1016/s0891-5849(02)01137-1. View

3.
Yao C, Zhang J, Liu G, Chen F, Lin Y . Neuroprotection by (-)-epigallocatechin-3-gallate in a rat model of stroke is mediated through inhibition of endoplasmic reticulum stress. Mol Med Rep. 2013; 9(1):69-76. DOI: 10.3892/mmr.2013.1778. View

4.
Ghasemi N, Razavi S, Nikzad E . Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy. Cell J. 2017; 19(1):1-10. PMC: 5241505. DOI: 10.22074/cellj.2016.4867. View

5.
Farias A, Spagnol G, Bordeaux-Rego P, Oliveira C, Fontana A, de Paula R . Vitamin D3 induces IDO+ tolerogenic DCs and enhances Treg, reducing the severity of EAE. CNS Neurosci Ther. 2013; 19(4):269-77. PMC: 6493393. DOI: 10.1111/cns.12071. View